

























Aging is associated with diverse and widespread 
changes in gene expression in different animal species 
[1]. The NF-κB transcription factor is one of the major 
regulators of gene expression associated with 
mammalian aging [2-3]. NF-κB controls the expression 
of genes involved in innate immunity, inflammation and 
apoptosis [2,3]. Such age-dependent pathologies as 
tissue inflammation and atrophy are caused by over-
activation of the NF-κB signaling with age [4-6]. We 
proposed that pharmacological inhibition of NF-κB will 
prevent age-related pathology and increase lifespan of 
Drosophila melanogaster. Three NF-κB transcription 
factors have been identified in Drosophila: Dorsal, Dif 
and Relish [7-9]. Like their vertebrate counterparts, 
these fly proteins contain an approximately 300-amino 
acid long, multifunctional and conserved Rel homology 
domain, which mediates dimerization, DNA binding, 
and interactions with IκB inhibitor proteins [7-9]. In this 
study we examined the effect of a specific NF-κB 
activity inhibitor, pyrrolidine dithiocarbamate (PDTC), 




In males pharmacological inhibition of NF-κB results in 
an increase of the median (by 20%) lifespan, as well as 
the age of 90 % mortality (by 14%), compared to males 
that did not receive PDTC treatment (Table, Figure 1). 
 
 























At the same time, the age-dependent mortality rate was 
not affected (χ
2  = 0; df = 1) (Table, Figure 2). In 
females, pharmacological inhibition of the NF-κB 
transcription factor causes an increase in the median (by 
13%) and maximum (by 11%) lifespan, as well as the 
age of 90 % mortality (by 6%), compared to females 
that did not receive PDTC treatment (Table, Figure 1). 
The inhibition of NF-κB factor increased the average 
and median lifespan (by 11-13%). The statistically 
significant decrease in the age-dependent mortality rate 
was detected in females as a result of NF-κB inhibitor 
effect (χ




Recent studies suggest that the NF-κB transcription 
factor controls age-dependent changes in inflammation 
genes expression. Donato et al showed that an increase 
of NF-κB dependent genes in human endothelium with 
age is primarily linked to decreased IκB-mediated NF-
κB inhibition [10]. Age-associated expression of NF-
κB-dependent genes cause progression of athero-
sclerosis in rat [11]. Furthermore, selective inhibition of 
NF-κB activity in blood vessel endothelial cells prevents 
atherosclerosis progression [12]. Genetic blockade of 
NF-κB in the skin of chronologically aged mice reverses 
the global gene expression program and tissue 
characteristics to those of young mice [13,14]. Decrease 
of NF-κB activity impedes progression of degenerative 
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sirtuin gene [15]. Kawahara et al suggested SIRT6 can 
prevent NF-κB-dependent gene overactivation via 
deacetylation of lysine 9 of the H3 histone (H3K9) on 
the promoters of NF-κB target genes, whereas over-
activation of NF-κB promotes normal and accelerated 
aging [15]. However, the effect of NF-κB inhibition on 



























pharmacological inhibition of NF-κB by pyrrolidine 
dithiocarbamate results in the considerable increase of 
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Pharmacological inhibition of NF-κB.  Pyrrolidine 
dithiocarbamate (PDTC, Sigma) was used as a specific 
inhibitor of the NF-κB transcription factor [16]. The 
experimental flies where treated with yeast paste 
containing 20 mg/l PDTC throughout the lifetime. 




Control and experimental flies were maintained at 
25±0.5°C in a 12 h-12 h light/dark cycle on a sugar-
yeast medium [17] covered with the yeast paste. To 
estimate the longevity 150-200 flies were collected 
during 24 h since the onset of eclosion (about 30 adult 
flies per 120 ml vial) for each experimental variant. 
Males and non-virgin females were kept separately. 
Flies were transferred to a fresh medium three times a 
week. Dead flies were counted daily. For each 
experimental variant 2-4 biological replicates were 
pooled. Survival functions were estimated using the 
Kaplan–Meier procedure and plotted as survival curves. 
Mean, median, minimum, and maximum lifespan, the 
age of 90% mortality were calculated. For aging rate 
estimates, the natural logarithm of age-dependent 
mortality rate ln(μ(х)) were used to determine the α and 
R0 parameters of the Gompertz equation (μ(х) = R0e
αx) 








calculated using the formula MRDT = ln2/α [18]. The 
statistical analysis of survival data was conducted using 
nonparametric methods. Comparison of survival 
functions was done using the modified Kolmogorov–
Smirnov test [19]. The statistical significance of 
differences between the median life spans for the 
experimental and control variants was determined using 
the Gehan–Breslow–Wilcoxon [20] and Mantel–Cox 
tests [21]. To test the statistical significance of differ-
ences in maximum lifespan (age of 90% mortality), the 
Wang–Allison test was used [22]. According Wang-
Allison test all animals from two compared variants 
were combined and the 90th percentile of the lifespan 
was calculated. Then each animal in each experimental 
variant was categorized into one of two groups: either 
lifespan above the 90th percentile or lifespan below the 
90th percentile. The 2×2 contingency table was used to 
record data. The ordinary χ2-test was used for an 
independent test of two experimental variants. 
Therefore, a test of the equality of proportions above the 
90th percentile across the variants was used as a test of 
the equality of the percentiles across the two variants 
[22]. The significance of differences in age-dependent 
mortality rate and initial mortality rate (parameters α 
and R0 in the Gompertz equation) was evaluated using 
the maximum likelihood method [23]. Statistical 
analysis was carried out using Statistica version 6.1, 








Table. Longevity parameters of flies after pharmacological inhibition of the transcription factor 
NF-κB activity by PDTC 
 
Variant Sex  x m ±Δ   M 90  %  Min  Max  MRDT  α R 0 n 
-PDTC 
Male 
42.8±0.3 44 56 3  72 7.3  0.095  0.0010  1156 
+PDTC  49.1±0.7 53* 64* 5 71  7.4 0.094  0.0005  381 
-PDTC 
Female 
58±0.4 61  72  9  82  6.7  0.104  0.00014  1187 
+PDTC  67.3±0.5 69* 76* 9 86  4.4 0.159*  0.0001  322 
 
 
x m ±Δ – mean lifespan and standard error of the mean; М – median lifespan; 90 % – age of 90 % mortality; Min and Max – 
minimum and maximum lifespan; α and R0 – Gompertz equation parameters; MRDT – mortality rate doubling time (ln2/α); n 
— sample size; +PDTC – PDTC treatment; -PDTC – without PDTC treatment. 
* p<0.001. 
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